

CYP2C19 *2/*2 Genotype is a Risk Factor for Multi-Site Arteriosclerosis: A Hospital-Based Cohort Study

Jieyao Xie, Tingjun Pan, Weiwen Luo, Songsheng Zhang, Yuquan Fang, Zhou Xu

Intensive Care Unit, Meizhou People's Hospital, Meizhou Academy of Medical Sciences, Meizhou, People's Republic of China

Correspondence: Jieyao Xie, Intensive Care Unit, Meizhou People's Hospital, Meizhou Academy of Medical Sciences, No. 63 Huangtang Road, Meijiang District, Meizhou, People's Republic of China, Email X1275014370@163.com

Background: Vascular diseases such as atherosclerosis usually affect multiple organs. Genetic factors have a certain proportion in the risk factors of atherosclerosis. The purpose was to investigate the relationship of cytochrome P450 2C19 (*CYP2C19*) polymorphisms with multi-site atherosclerosis.

Methods: The study included 410 patients with single-site atherosclerosis and 529 patients with multi-site atherosclerosis. The relationship between *CYP2C19* rs4244285 and rs4986893 polymorphisms and single-site atherosclerosis and multi-site atherosclerosis was analyzed.

Results: The proportion of *CYP2C19* rs4244285 A allele (35.9% vs 29.9%, $P=0.007$) and rs4986893 G allele (97.7% vs 94.8%, $P=0.001$) in multi-site atherosclerosis group was significantly higher than that in single-site atherosclerosis group. The distribution of *CYP2C19* genotypes was significantly different between the two groups ($P=0.002$). The results of univariate logistic regression indicated that *CYP2C19* *1/*3 genotype (*1/*3 vs *1/*1: odds ratio (OR) 0.456, 95% confidence interval (CI): 0.231–0.902, $P=0.024$) may decrease risk of multi-site atherosclerosis, while *2/*2 genotype (*2/*2 vs *1/*1: OR 1.780, 95% CI: 1.100–2.880, $P=0.019$) may increase risk of multi-site atherosclerosis. Multivariate logistic regression (adjusted for gender, age, smoking, drinking, hypertension, and diabetes) indicated that *CYP2C19* *1/*3 genotype (*1/*3 vs *1/*1: OR 0.459, 95% CI: 0.231–0.909, $P=0.026$) may be an independent protective factor for multi-site atherosclerosis, while *2/*2 genotype (*2/*2 vs *1/*1: OR 1.767, 95% CI: 1.091–2.864, $P=0.021$) may be an independent risk factor for multi-site atherosclerosis.

Conclusion: *CYP2C19* *1/*3 genotype may be an independent protective factor for multi-site atherosclerosis, while *2/*2 genotype may be an independent risk factor for multi-site atherosclerosis.

Keywords: CYP2C19, genotype, multi-site atherosclerosis, polyvascular disease

Introduction

The incidence of cardiovascular and cerebrovascular diseases is on the rise at present.^{1,2} Atherosclerosis is the main pathological basis of many cardiovascular and cerebrovascular diseases.³ Atherosclerosis is a chronic disease of arterial wall and is caused by the damage of the intima of the artery by risk factors, the deposition of lipids in the intima of the artery, the chronic inflammatory reaction of the artery wall, and the gradual formation of atherosclerotic plaque.^{4–6} The formation of atherosclerotic plaque and plaque rupture cause platelet activation and aggregation, plaque surface and cavity thrombosis, and eventually leads to vascular stenosis and occlusion, resulting in a variety of diseases.⁷ With the local immune response and lipid infiltration of the intima, the proliferation of fibrous tissue and the formation of calcium deposits can lead to plaque rupture and thrombosis.⁸ Atherosclerosis can sometimes involve multiple vessels or multiple sites of a vessel. Polyvascular disease refers to clinically obvious atherosclerosis in multiple arterial sites (coexisting disease in ≥ 2 arterial beds), which is regarded as a disease prone to cardiovascular and cerebrovascular adverse events, and has been widely concerned.^{9,10}

The occurrence of atherosclerosis is influenced by a number of factors, especially alcohol abuse and chronic hyperlipidemia, and the other risk factors include smoking, hypertension, diabetes, ambient air pollution and noise.^{11,12} Atherosclerosis is also related to genetic factors.¹³ Cytochrome P450 (CYP450) superfamily is involved in the metabolism of endogenous and exogenous substances.¹⁴ The occurrence and progression of many diseases may be related to the CYP450 family.¹⁵ Cytochrome P450 2C19 (CYP2C19) is a member of the CYP450 family.¹⁶ Arachidonic acid (AA) can be metabolized by CYP2C19 into endodermal hyperpolarized factor (EDHF),¹⁷ while EDHF is beneficial to vascular dilation and inhibits vascular calcification.¹⁸ Reactive oxygen species (ROS) produced by coronary endothelial cells in the process of CYP2C19-catalyzed reaction¹⁹ is a risk factor for atherosclerosis.^{20,21}

CYP2C19 is encoded by the *CYP2C19* gene. The single-nucleotide polymorphisms (SNPs) rs4244285 and rs4986893 are the most common polymorphisms of *CYP2C19* gene. *CYP2C19**2 (rs4244285, 681G>A) and *CYP2C19**3 (rs4986893, 636G>A) are defined as loss-of-function (LOF) alleles related to decreased platelet response to clopidogrel or increased incidence of clopidogrel resistance.²² According to its ability to metabolize drugs, CYP2C19 enzyme can be divided into three phenotypes: extensive metabolizer (EM) type, intermediate metabolizer (IM) type, and poor metabolizer (PM) type. The metabolic phenotype of wild-type genotype (*CYP2C19**1/*1) was EM type. The CYP2C19 activity of the mutant heterozygote (*CYP2C19**1/*2, or *1/*3) was weakened, and its metabolic phenotype is IM type. The metabolic activity of CYP2C19 encoded by the mutant homozygote (*CYP2C19**2/*2, *2/*3, or *3/*3) is completely lost, and its metabolic phenotype is PM type.²³ At present, studies on CYP2C19 mainly focus on the relationship between *CYP2C19* polymorphism and treatment effect and response to clopidogrel in patients with arterial disease.^{24,25} However, there are relatively few studies on the relationship between *CYP2C19* polymorphism and atherosclerosis susceptibility. The *CYP2C19**2 frequency in Han patients with coronary artery disease (CAD) was significantly higher than that in Han healthy groups, while the *CYP2C19**3 frequency in Uygur patients with coronary artery disease was significantly lower than that in Uygur healthy groups, in Northwestern Xinjiang, China.²⁶ The *CYP2C19**3 was an independent risk factor for CAD in a Uighur population.²⁷ *CYP2C19* PM might be associated with the susceptibility of CAD in women from a Japanese population.²⁸ *CYP2C19* loss-of-function allele was a risk factor for ischemic stroke event in an American population.²⁹ *CYP2C19* loss-of-function allele was a risk factor for stroke composite events in a Caucasian population.²⁵

Differences in ethnicity, lifestyle and genetic background can affect the onset and progression of atherosclerosis.^{15,30,31} However, the study in the relationship of *CYP2C19* gene polymorphisms and multi-site atherosclerosis is still at a blank stage. In the current study, we evaluated the association between *CYP2C19* gene polymorphisms and single- or multi-site atherosclerosis.

Materials and Methods

Study Population

This study retrospectively analyzed the clinical data of 410 patients with single-site atherosclerosis and 529 patients with multi-site atherosclerosis who were admitted to Meizhou People's Hospital in China from January 2016 to July 2019. This study was approved by the Ethics Committee of Meizhou People's Hospital.

Arteriosclerosis is determined by tests such as angiography, magnetic resonance imaging (MRI), computed tomography (CT) or color Doppler flow imaging (CDFI). Plaque was defined as a focal structure that invaded the lumen of the artery by at least 0.5 mm, or by 50% of the surrounding endo-media thickness, or by a thickness greater than 1.5 mm measured from the outer membrane to the endo-lumen interface.³² The diagnosis of atherosclerosis was determined by two senior radiologists evaluating the results of imaging examinations in a double-blind evaluation. In the presence of atherosclerotic plaque, thickening of the vessel wall is seen with or without lumen stenosis.^{33,34} In this study, atherosclerosis was observed in coronary artery, carotid artery, cerebral artery, and limb artery. The inclusion criteria were as follows: (1) Clinically diagnosed as atherosclerosis; (2) The clinical data of the patients were complete; (3) Adults. The exclusion criteria were as follows: (1) Incomplete clinical data of the patients; (2) Atherosclerosis patients with severe infectious diseases, autoimmune diseases, organ insufficiency and other diseases.

The demographic characteristics, personal history and disease history (vascular risk factors) of patients were collected from the Hospital Information System (HIS). The diagnostic criteria for hypertension are systolic blood pressure of

≥ 140 mm Hg, diastolic blood pressure of ≥ 90 mm Hg.³⁵ The diagnostic criteria for diabetes were fasting blood glucose ≥ 126.1 mg/dL, blood glucose ≥ 200 mg/dL 2 hours after loading.³⁶

Genetic Analysis

Genomic DNA was extracted from whole blood using a QIAamp DNA Blood Mini Kit (Qiagen GmbH, North Rhine-Westphalia, Germany). *CYP2C19* variants were detected by *CYP2C19* genotyping kit (BaiO Technology Co., Ltd, Shanghai, China) with PCR-gene chip method.³⁷ The specific detection steps are carried out by referring to the method published by our colleagues before.³⁷

Statistical Analysis

Data analysis was performed using SPSS statistical software version 21.0 (IBM Inc., USA). Categorical variables are expressed as percentages. The differences of genotype composition ratios and allele frequencies among patients with single- and multi-site atherosclerosis were analyzed by the χ^2 test. The significance of the Hardy-Weinberg equilibrium (HWE) of the *CYP2C19* polymorphisms in the patients was analyzed by the χ^2 test. The level of significance adopted was $P < 0.05$ in single- and multi-site atherosclerosis patients. To measure the relative risk of *CYP2C19* genotype, multiple regression analysis was performed after adjusting for the factors of demographic characteristics, personal history and disease history. $P < 0.05$ was used as the level of statistical significance for all statistical analyses in this study.

Results

Characteristics of Subjects

This study included 939 individuals, including 645 (68.7%) men and 294 (31.3%) women. There were 303 (32.3%) patients < 65 years old and 636 (67.7%) patients ≥ 65 years old. There were 410 patients with single-site atherosclerosis and 529 patients with multi-site atherosclerosis in this study. There were no significant differences in age distribution, gender distribution, proportion of patients with a history of smoking and alcohol consumption, and proportion of patients with hypertension and diabetes between the single- and multi-site atherosclerosis groups (all $P > 0.05$) (Table 1).

Frequencies of *CYP2C19* rs4244285 and rs4986893 Genotypes in Patients with Single-Site Atherosclerosis and Multi-Site Atherosclerosis

The χ^2 test was used to test the significance of the Hardy-Weinberg equilibrium of the polymorphism of the *CYP2C19* gene in the patients with single-site atherosclerosis and patients with multi-site atherosclerosis. The genotype distributions of *CYP2C19* rs4244285 (*CYP2C19* *2) in patients with single-site arteriosclerosis ($\chi^2 = 2.421$, $P = 0.120$) and patients with multi-site arteriosclerosis ($\chi^2 = 0.981$, $P = 0.322$) were consistent with Hardy-Weinberg equilibrium, respectively. The genotype distributions of *CYP2C19* rs4986893 (*CYP2C19* *3) in patients with single-site atherosclerosis ($\chi^2 = 0.752$, $P = 0.386$) and patients with multi-

Table 1 Clinical Characteristics of Patients with Single-Site Arteriosclerosis and Patients with Multi-Site Arteriosclerosis

	Total (n=939)	Patients with Single-Site Arteriosclerosis (n=410)	Patients with Multi-Site Arteriosclerosis (n=529)	P values
Age, years				
<65, n(%)	303 (32.3)	138 (33.7)	165 (31.2)	0.439
≥ 65 , n(%)	636 (67.7)	272 (66.3)	364 (68.8)	
Gender				
Male, n(%)	645 (68.7)	281 (68.5)	364 (68.8)	0.944
Female, n(%)	294 (31.3)	129 (31.5)	165 (31.2)	
History of smoking, n(%)	195 (20.8)	86 (21.0)	109 (20.6)	0.935
History of alcohol consumption, n(%)	33 (3.5)	14 (3.4)	19 (3.6)	1.000
Hypertension, n(%)	628 (66.9)	263 (64.1)	365 (69.0)	0.124
Diabetes, n(%)	300 (31.9)	133 (32.4)	167 (31.6)	0.778

site atherosclerosis ($\chi^2=2.037$, $P=0.153$) were consistent with Hardy-Weinberg equilibrium, respectively. The frequencies of *CYP2C19* rs4244285 and rs4986893 genotypes and alleles were compared between the single and multi-site atherosclerosis groups. The proportion of *CYP2C19* rs4244285 A allele in multi-site atherosclerosis group was significantly higher than that in single-site atherosclerosis group (35.9% vs 29.9%, $P=0.007$). The proportion of *CYP2C19* rs4986893 G allele in multi-site atherosclerosis group was significantly higher than that in single-site atherosclerosis group (97.7% vs 94.8%, $P=0.001$) (Table 2).

The percentages of *CYP2C19**1, *CYP2C19**2, and *CYP2C19**3 alleles were 63.2%, 33.3%, and 3.6%, respectively. Of the 939 individuals included in this study, 575 (61.2%) were carriers of *CYP2C19**2 or *3 LOF allele. The distribution of *CYP2C19* genotypes was significantly different between the single- and multi-site atherosclerosis groups ($P=0.002$). The distribution of *CYP2C19**1, *2, and *3 alleles was significantly different between the two groups ($P<0.001$) (Table 3).

Table 2 Frequencies of *CYP2C19* Genotypes in Patients with Single-Site Arteriosclerosis and Patients with Multi-Site Arteriosclerosis

Genotype/Allele	Total (n=939)	Patients with Single-Site Arteriosclerosis (n=410)	Patients with Multi-Site Arteriosclerosis (n=529)	P value
<i>CYP2C19</i> *2 (rs4244285)				
G/G	407(43.3%)	195(47.6%)	212(40.1%)	0.016
G/A	439(46.8%)	185(45.1%)	254(48.0%)	
A/A	93(9.9%)	30(7.3%)	63(11.9%)	
G	1253(66.7%)	575(70.1%)	678(64.1%)	0.007
A	625(33.3%)	245(29.9%)	380(35.9%)	
HWE (χ^2 , P)	$\chi^2=2.614$, $P=0.106$	$\chi^2=2.421$, $P=0.120$	$\chi^2=0.981$, $P=0.322$	
<i>CYP2C19</i> *3 (rs4986893)				
G/G	875(93.2%)	369(90.0%)	506(95.7%)	0.001
G/A	61(6.5%)	39(9.5%)	22(4.2%)	
A/A	3(0.3%)	2(0.5%)	1(0.2%)	
G	1811(96.4%)	777(94.8%)	1034(97.7%)	0.001
A	67(3.6%)	43(5.2%)	24(2.3%)	
HWE (χ^2 , P)	$\chi^2=2.931$, $P=0.087$	$\chi^2=0.752$, $P=0.386$	$\chi^2=2.037$, $P=0.153$	

Abbreviation: HWE, Hardy Weinberg Equilibrium.

Table 3 Distribution of *CYP2C19* Genotypes, *CYP2C19**2 and *CYP2C19**3 Loss-of-Function Alleles in the Study Population

Genotype	Total (n=939)	Patients with Single-Site Arteriosclerosis (n=410)	Patients with Multi-Site Arteriosclerosis (n=529)	P value
Genotypes				0.002
*1/*1	364(38.8%)	167(40.7%)	197(37.2%)	
*1/*2	418(44.5%)	172(42.0%)	246(46.5%)	
*1/*3	40(4.3%)	26(6.3%)	14(2.6%)	
*2/*2	93(9.9%)	30(7.3%)	63(11.9%)	
*2/*3	21(2.2%)	13(3.2%)	8(1.5%)	
*3/*3	3(0.3%)	2(0.5%)	1(0.2%)	
Alleles				<0.001
*1	1186(63.2%)	532(64.9%)	654(61.8%)	
*2	625(33.3%)	245(29.9%)	380(35.9%)	
*3	67(3.6%)	43(5.2%)	24(2.3%)	

Table 4 Association of the Risk Factors with Multi-Site Arteriosclerosis

Variables		Univariate OR (95% CI)	P values	Multivariate OR (95% CI)	P values
Age (≥ 65 / <65)		1.119(0.850–1.474)	0.423	1.093(0.820–1.459)	0.543
Gender (Male/ Female)		1.013(0.767–1.337)	0.929	0.998(0.739–1.349)	0.992
History of smoking (Yes/No)		0.978(0.712–1.343)	0.890	0.992(0.696–1.414)	0.964
History of alcohol consumption (Yes/No)		1.054(0.522–2.128)	0.884	1.060(0.513–2.191)	0.874
Hypertension (Yes/No)		1.244(0.947–1.635)	0.117	1.269(0.959–1.678)	0.095
Diabetes (Yes/No)		0.961(0.729–1.267)	0.777	0.926(0.698–1.228)	0.593
<i>CYP2C19</i>	*1/*1	1.000(reference)		1.000(reference)	
	*1/*2	1.212(0.913–1.610)	0.183	1.209(0.908–1.609)	0.194
	*1/*3	0.456(0.231–0.902)	0.024	0.459(0.231–0.909)	0.026
	*2/*2	1.780(1.100–2.880)	0.019	1.767(1.091–2.864)	0.021
	*2/*3	0.522(0.211–1.289)	0.159	0.498(0.200–1.236)	0.133
	*3/*3	0.424(0.038–4.716)	0.485	0.435(0.039–4.915)	0.501

Association of the Risk Factors with Multi-Site Atherosclerosis

To gain insight into the independent risk factors on multi-site atherosclerosis, logistic regression analysis was performed. The results of univariate logistic regression showed that *CYP2C19* *1/*3 genotype (*1/*3 vs *1/*1: odds ratio (OR) 0.456, 95% confidence interval (CI): 0.231–0.902, $P=0.024$) may decrease risk of multi-site atherosclerosis, while *2/*2 genotype (*2/*2 vs *1/*1: OR 1.780, 95% CI: 1.100–2.880, $P=0.019$) may increase risk of multi-site atherosclerosis.

The results of multivariate logistic regression (adjusted for gender, age, smoking, drinking, hypertension, and diabetes) indicated that *CYP2C19* *1/*3 genotype (*1/*3 vs *1/*1: OR 0.459, 95% CI: 0.231–0.909, $P=0.026$) may be an independent protective factor for multi-site atherosclerosis, while *2/*2 genotype (*2/*2 vs *1/*1: OR 1.767, 95% CI: 1.091–2.864, $P=0.021$) may be an independent risk factor for multi-site atherosclerosis (Table 4).

Discussion

The result of the relationship of *CYP2C19* gene polymorphisms and multi-site atherosclerosis is still unclear. In the current study, the relationship between *CYP2C19* rs4244285 and rs4986893 polymorphisms and single-site atherosclerosis and multi-site atherosclerosis was analyzed.

In this study, the proportion of *CYP2C19* rs4244285 A allele in multi-site atherosclerosis group was significantly higher than that in single-site atherosclerosis group, while the proportion of *CYP2C19* rs4986893 G allele in multi-site atherosclerosis group was significantly higher than that in single-site atherosclerosis group. The distribution of *CYP2C19* genotypes was significantly different between the single- and multi-site atherosclerosis groups. Multivariate logistic regression showed that *CYP2C19* *1/*3 genotype may be an independent protective factor for multi-site atherosclerosis, while *2/*2 genotype may be an independent risk factor for multi-site atherosclerosis. In endothelial cells, CYP2C-mediated arachidonic acid endothelium-derived hyperpolarizing factor (EDHF) metabolite is the most important cause of endothelial relaxation.¹⁷ Reactive oxygen species (ROS) produced by CYP2C19 catalyzed reactions, excessive ROS can have harmful effects on arterial endothelial cells.¹⁵ Generally speaking, the mechanism by which CYP2C19 is involved in the process of atherosclerosis may be related to its role in the metabolism of vascular endothelial cells and vascular endothelial biology.^{17–21} There may be differences in the levels of metabolic substrates at different arterial sites. Different *CYP2C19* genotypes express different CYP2C19 enzymes with different conformations, affecting their ability to bind to substrates at different arterial sites.³⁸ Several studies have reported the relationship between *CYP2C19* polymorphism and susceptibility to atherosclerosis.^{26–29} To our knowledge, this study is the first report of the relationship of *CYP2C19* genotypes and multi-site atherosclerosis.

In this study, the percentages of *CYP2C19* *2 and *3 alleles were 33.3% and 3.6%, respectively. It is consistent with the results of a study based on the Chinese Han population.³⁹ The prevalence of the *CYP2C9**2 and *3 alleles was 53.1% and 10.2% in a Taiwanese population,⁴⁰ 20.5% and 2.5% in a Vietnamese population,⁴¹ 25.6% and 2.5% in a Thai population.⁴² In the European populations, the prevalence of the *CYP2C9**2 and *3 alleles was 13.6% and 7.4% in the population from the Republic of Srpska in Bosnia and Herzegovina,⁴³ 13.1% and 0% in a Greek population.⁴⁴ The

prevalence levels of *2 and *3 alleles in the Caucasian population were 13.3% and 5.3%, respectively.⁴⁵ On the African continent, the percentages of *CYP2C19* *2 and *3 alleles were 11.38% and 0% in a Moroccan population,⁴⁶ 6% and 0% in a Ghanaian population,⁴⁷ 12.6% and 0.3% in an Egyptian population.⁴⁸ The *CYP2C19**2 allele is present in only about 13% of the Middle Eastern population.^{49,50} In the American population, the proportion of the *CYP2C19**2 allele is about 8%.^{51,52} In general, the frequencies of *CYP2C19* LOF alleles are relatively high in Southeast Asian populations.

Studies on the relationship between traditional influencing factors and atherosclerosis risk have also had some inconsistent results. In this study, multivariate logistic regression showed no significant relationship between gender, age, smoking, alcohol consumption, hypertension, and diabetes and the risk of multi-site atherosclerosis. Study has shown that smoking, alcohol abuse, a history of hypertension and diabetes are risk factors that increase the likelihood of developing cardiovascular disease.⁵³ A study has found that the incidence of arterial disease may be different between men and women.⁵⁴ It can be seen that the occurrence of atherosclerosis is the result of genetic factors, environmental factors, living habits and other comprehensive effects. The inconsistent results between different studies may be related to the number of patients included and the influencing factors analyzed.

Our study found that *CYP2C19* *1/*3 genotype may be an independent protective factor for multi-site atherosclerosis, while *2/*2 genotype may be an independent risk factor for multi-site atherosclerosis. To our knowledge, this study is the first report of the relationship of *CYP2C19* genotypes and multi-site atherosclerosis. The strengths of our study include that we analyzed atherosclerosis at multiple vascular sites, and the number of included cases was not small. However, there are some limitations in this study. First, the association between these polymorphisms and the degree of atherosclerosis (atherosclerosis index or grade I-IV) was not investigated in this study because this study is a retrospective study. Second, it is a study conducted among single- and multi-site atherosclerosis patients in a medical institution, there was inevitably selection bias as the population is not completely representative. Third, this study only studied the common polymorphisms of *CYP2C19* gene, and did not investigate the relationship between the full-length variation of *CYP2C19* gene and the risk of multi-site atherosclerosis. Future studies that include larger sample sizes, the degree of atherosclerosis, and the analysis of the full-length variation of *CYP2C19* gene are needed.

Conclusion

In the cohort of this study, we found that *CYP2C19* *2/*2 genotype is an independent risk factor for multi-site atherosclerosis after adjusting for the factors of demographic characteristics, personal history and disease history.

Data Sharing Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethics Approval

All participants were informed on the study procedures and goals and the study obtained written informed consent from all the participants. We confirm that all methods were performed in accordance with relevant guidelines and regulations. The study was performed under the guidance of the Declaration of Helsinki and approved by the Ethics Committee of Medicine, Meizhou People's Hospital.

Acknowledgments

The authors would like to thank their colleagues who were not listed in the authorship of the Intensive Care Unit, Meizhou People's Hospital, for their helpful comments on the manuscript.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

This study was supported by the Science and Technology Program of Meizhou (Grant No.: 2019B0202001).

Disclosure

The authors declare that they have no competing interests in this work.

References

1. Turana Y, Tenglawan J. Hypertension and stroke in Asia: a comprehensive review from HOPE Asia. *J Clin Hypertens*. 2021;23(3):513–521. doi:10.1111/jch.14099
2. Ji E, Lee S. Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases. *Int J Mol Sci*. 2021;22(11):5770. doi:10.3390/ijms22115770
3. Zhang ZZ, Wang G, Yin SH, Yu XH. C1q Tumor Necrosis Factor-Related Protein 1: a Promising Therapeutic Target for Atherosclerosis. *J Cardiovasc Pharmacol*. 2022;79(3):273–280. doi:10.1097/FJC.0000000000001186
4. Jing L, Shu-Xu D, Yong-Xin R. A review: pathological and molecular biological study on atherosclerosis. *Clin Chim Acta*. 2022;531:217–222. doi:10.1016/j.cca.2022.04.012
5. Gutierrez J, Turan TN, Hoh BL, Chimowitz MI. Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment. *Lancet Neurol*. 2022;21(4):355–368. doi:10.1016/S1474-4422(21)00376-8
6. Marchio P, Guerra-Ojeda S, Vila JM. Targeting Early Atherosclerosis: a Focus on Oxidative Stress and Inflammation. *Oxid Med Cell Longev*. 2019;2019:8563845. doi:10.1155/2019/8563845
7. Shamaki GR, Markson F, Soji-Ayoade D, Agwuegbo CC, Bamgbose MO, Tamunoinemi BM. Peripheral Artery Disease: a Comprehensive Updated Review. *Curr Probl Cardiol*. 2022;47(11):101082. doi:10.1016/j.cpcardiol.2021.101082
8. Park TS, Devi S, Sharma A, Kim GT, Cho KH. De Novo Sphingolipid Biosynthesis in Atherosclerosis. *Adv Exp Med Biol*. 2022;1372:31–46. doi:10.1007/978-981-19-0394-6_3
9. Aday AW, Matsushita K. Epidemiology of Peripheral Artery Disease and Polyvascular Disease. *Circ Res*. 2021;128(12):1818–1832. doi:10.1161/CIRCRESAHA.121.318535
10. Gutierrez JA, Aday AW, Patel MR, Jones WS. Polyvascular Disease: reappraisal of the Current Clinical Landscape. *Circ Cardiovasc Interv*. 2019;12(12):e007385. doi:10.1161/CIRCINTERVENTIONS.119.007385
11. Zhou F, Tang J, Li P, Liao B, Qin C. Distribution of cerebral artery stenosis and risk factors in ethnic Zhuang and Han patients with ischemic stroke in Guangxi province. *Ann Palliat Med*. 2020;9(2):256–263. doi:10.21037/apm.2020.02.32
12. Lechner K, von Schacky C, McKenzie AL, et al. Lifestyle factors and high-risk atherosclerosis: pathways and mechanisms beyond traditional risk factors. *Eur J Prev Cardiol*. 2020;27(4):394–406. doi:10.1177/2047487319869400
13. Abraham G, Rutten-Jacobs L, Inouye M. Risk Prediction Using Polygenic Risk Scores for Prevention of Stroke and Other Cardiovascular Diseases. *Stroke*. 2021;52(9):2983–2991. doi:10.1161/STROKEAHA.120.032619
14. Li Z, Jiang Y, Guengerich FP. Engineering cytochrome P450 enzyme systems for biomedical and biotechnological applications. *J Biol Chem*. 2020;295(3):833–849. doi:10.1074/jbc.REV119.008758
15. Elfaki I, Mir R, Almutairi FM, Duhier FMA. Cytochrome P450: polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis. *Asian Pac J Cancer Prev*. 2018;19(8):2057–2070. doi:10.22034/APJCP.2018.19.8.2057
16. Lee CR, Luzum JA, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. *Clin Pharmacol Ther*. 2022;112(5):959–967. doi:10.1002/cpt.2526
17. Fisslthaler B, Fleming I, Busse R. EDHF: a cytochrome P450 metabolite in coronary arteries. *Semin Perinatol*. 2000;24(1):15–19. doi:10.1016/s0146-0005(00)80048-8
18. Chawengsub Y, Gauthier KM, Campbell WB. Role of arachidonic acid lipoxigenase metabolites in the regulation of vascular tone. *Am J Physiol Heart Circ Physiol*. 2009;297(2):H495–507. doi:10.1152/ajpheart.00349.2009
19. Fleming I, Michaelis UR, Brendenkötter D, et al. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. *Circ Res*. 2001;88(1):44–51. doi:10.1161/01.res.88.1.44
20. Malekmohammad K, Sewell RDE. Antioxidants and Atherosclerosis: mechanistic Aspects. *Biomolecules*. 2019;9(8):301. doi:10.3390/biom9080301
21. Negre-Salvayre A, Guerby P, Gayral S, Laffargue M, Salvayre R. Role of reactive oxygen species in atherosclerosis: lessons from murine genetic models. *Free Radic Biol Med*. 2020;149:8–22. doi:10.1016/j.freeradbiomed.2019.10.011
22. Ma L, Yuan Y, Li J, Yu C, Zhao J. Distribution of CYP2C19, ABCB1 and PON1 polymorphisms in Chinese Han, Hui, Uygur and Kazak patients with coronary atherosclerotic heart disease. *Int J Immunogenet*. 2020;47(6):539–545. doi:10.1111/iji.12511
23. Yang E, Kim S, Kim B, et al. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. *Br J Clin Pharmacol*. 2022;88(7):3288–3296. doi:10.1111/bcp.15268
24. Huang S, Yang S, Ly S, et al. Clinical non-effectiveness of clopidogrel use for peripheral artery disease in patients with CYP2C19 polymorphisms: a systematic review. *Eur J Clin Pharmacol*. 2022;78(8):1217–1225. doi:10.1007/s00228-022-03346-7
25. Jafrin S, Naznin NE, Reza MS, Aziz MA, Islam MS. Risk of stroke in CYP2C19 LoF polymorphism carrier coronary artery disease patients undergoing clopidogrel therapy: an ethnicity-based updated meta-analysis. *Eur J Intern Med*. 2021;90:49–65. doi:10.1016/j.ejim.2021.05.022
26. Wang T, Zhao T, Bao S, et al. CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in Northwestern Xinjiang, China, From 2014 Through 2019. *Medicine*. 2020;99(29):e20582. doi:10.1097/MD.00000000000020582
27. Yang YN, Wang XL, Ma YT, et al. Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease in a Uighur population. *Clin Appl Thromb Hemost*. 2010;16(5):579–583. doi:10.1177/1076029610364522
28. Hokimoto S, Tabata N, Akasaka T, et al. Gender differences in impact of CYP2C19 polymorphism on development of coronary artery disease. *J Cardiovasc Pharmacol*. 2015;65(2):148–152. doi:10.1097/FJC.000000000000171

29. Patel PD, Vimalathas P, Niu X, et al. CYP2C19 Loss-of-Function is Associated with Increased Risk of Ischemic Stroke after Transient Ischemic Attack in Intracranial Atherosclerotic Disease. *J Stroke Cerebrovasc Dis.* 2021;30(2):105464. doi:10.1016/j.jstrokecerebrovasdis.2020.105464
30. Kubota M, Yoneda M, Watanabe H, Egusa G. Progression of Carotid Atherosclerosis in Two Japanese Populations with Different Lifestyles. *J Atheroscler Thromb.* 2017;24(10):1069–1074. doi:10.5551/jat.39578
31. Liu Y, Wang X, Zhang Q, et al. Relationship Between Dietary Patterns and Carotid Atherosclerosis Among People Aged 50 Years or Older: a Population-Based Study in China. *Front Nutr.* 2021;8:723726. doi:10.3389/fnut.2021.723726
32. Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intima-media thickness and plaque consensus (2004–2006–2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. *Cerebrovasc Dis.* 2012;34(4):290–296. doi:10.1159/000343145
33. Qiao Y, Guallar E, Suri FK, et al. MR Imaging Measures of Intracranial Atherosclerosis in a Population-based Study. *Radiology.* 2016;280(3):860–868. doi:10.1148/radiol.2016151124
34. Wu FZ, Wu MT. 2014 SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. *J Cardiovasc Comput Tomogr.* 2015;9(2):e3. doi:10.1016/j.jcct.2015.01.003
35. Wang Z, Chen Z, Zhang L, et al. Status of Hypertension in China: results From the China Hypertension Survey, 2012–2015. *Circulation.* 2018;137(22):2344–2356. doi:10.1161/CIRCULATIONAHA.117.032380
36. Wang L, Gao P, Zhang M, et al. Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013. *JAMA.* 2017;317(24):2515–2523. doi:10.1001/jama.2017.7596
37. Cai N, Li C, Gu X, et al. CYP2C19 loss-of-function is associated with increased risk of hypertension in a Hakka population: a case-control study. *BMC Cardiovasc Disord.* 2023;23(1):185. doi:10.1186/s12872-023-03207-w
38. Reynald RL, Sansen S, Stout CD, Johnson EF. Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19. *J Biol Chem.* 2012;287(53):44581–44591. doi:10.1074/jbc.M112.424895
39. He L, Chen S, Li J, et al. Genetic and phenotypic frequency distribution of CYP2C9, CYP2C19 and CYP2D6 in over 3200 Han Chinese. *Clin Exp Pharmacol Physiol.* 2020;47(10):1659–1663. doi:10.1111/1440-1681.13357
40. Lee YC, Liao YC, Chang FC, Huang HC, Tsai JY, Chung CP. Investigating CYP2C19 loss-of-function allele statuses and their association with stroke of different etiologies in a Taiwanese population. *J Chin Med Assoc.* 2019;82(6):469–472. doi:10.1097/JCMA.000000000000101
41. Vu NP, Nguyen HTT, Tran NTB, et al. CYP2C19 genetic polymorphism in the Vietnamese population. *Ann Hum Biol.* 2019;46(6):491–497. doi:10.1080/03014460.2019.1687750
42. Sukprasong R, Chuwongwattana S, Koomdee N, et al. Allele frequencies of single nucleotide polymorphisms of clinically important drug-metabolizing enzymes CYP2C9, CYP2C19, and CYP3A4 in a Thai population. *Sci Rep.* 2021;11(1):12343. doi:10.1038/s41598-021-90969-y
43. Vidović S, Škrbić R, Stojiljković MP, et al. Prevalence of five pharmacologically most important CYP2C9 and CYP2C19 allelic variants in the population from the Republic of Srpska in Bosnia and Herzegovina. *Arh Hig Rada Toksikol.* 2021;72(3):129–134. doi:10.2478/aiht-2021-72-3499
44. Arvanitidis K, Ragia G, Iordanidou M, et al. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. *Fundam Clin Pharmacol.* 2007;21(4):419–426. doi:10.1111/j.1472-8206.2007.00510.x
45. Myrand SP, Sekiguchi K, Man MZ, et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. *Clin Pharmacol Ther.* 2008;84(3):347–361. doi:10.1038/sj.cpt.6100482
46. Afilal D, Basselam MA, Brakez Z, Chouham S, Brehm A, Izaabel EH. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population. *Genet Test Mol Biomarkers.* 2017;21(5):298–304. doi:10.1089/gtmb.2016.0304
47. Kudzi W, Doodoo AN, Mills JJ. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. *BMC Med Genet.* 2009;10:124. doi:10.1186/1471-2350-10-124
48. Khalil BM, Shahin MH, Solayman MH, et al. Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population. *Clin Transl Sci.* 2016;9(1):23–28. doi:10.1111/cts.12383
49. Saber MM, Boroumand M, Behmanesh M. Investigation of CYP2C19 allele and genotype frequencies in Iranian population using experimental and computational approaches. *Thromb Res.* 2014;133(2):272–275. doi:10.1016/j.thromres.2013.11.005
50. Djaffar Jureidini I, Chamseddine N, Keleshian S, Naoufal R, Zahed L, Hakime N. Prevalence of CYP2C19 polymorphisms in the Lebanese population. *Mol Biol Rep.* 2011;38(8):5449–5452. doi:10.1007/s11033-011-0700-y
51. Bravo-Villalta HV, Yamamoto K, Nakamura K, Bayá A, Okada Y, Horiuchi R. Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study. *Eur J Clin Pharmacol.* 2005;61(3):179–184. doi:10.1007/s00228-004-0890-5
52. de Andrés F, Altamirano-Tinoco C, Ramírez-Roa R, Montes-Mondragón CF, Dorado P. Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population. *Pharmacogenomics J.* 2021;21(2):140–151. doi:10.1038/s41397-020-00190-9
53. Pastore I, Bolla AM, Montefusco L, et al. The Impact of Diabetes Mellitus on Cardiovascular Risk Onset in Children and Adolescents. *Int J Mol Sci.* 2020;21(14):4928. doi:10.3390/ijms21144928
54. Pabon M, Cheng S. Sex Differences in Peripheral Artery Disease. *Circ Res.* 2022;130(4):496–511. doi:10.1161/CIRCRESAHA.121.320702